<DOC>
	<DOCNO>NCT00175994</DOCNO>
	<brief_summary>The purpose study : - To determine absolute bioavailability voriconazole single oral dose ( 400 mg voriconazole [ VFEND brand ] ) comparison intravenous ( i.v . ) administration ( 400 mg VFEND , equivalent two 10 mg/ml-infusates , contain 200 mg voriconazole [ VRC ] ) healthy individual stratify accord three predominant CYP2C19 genotypes - To investigate possible pathway metabolism modulation accord genetic polymorphism CYP2C19 i.v . oral administration VRC .</brief_summary>
	<brief_title>Bioavailability Metabolism Voriconazole Relation Its Modulation CYP2C19 Genetic Polymorphism</brief_title>
	<detailed_description>As CYPs mainly involve VRC metabolism likely also gut wall metabolism CYPs occur . However , substantial first pas metabolism VRC report . In human VRC metabolism study systematically . It therefore important ass VRC metabolism addition influence CYP2C19 genetic polymorphism formation different VRC metabolite .</detailed_description>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Good state health ( physically mentally ) Any regular drug treatment within last two month except oral contraceptive female participant Any intake substance know induce inhibit drug metabolise enzyme transport system enzymes within period le 10 time respective elimination halflife Any acute chronic illness clinically relevant finding prestudy examination Allergies ( except mild form hay fever ) history hypersensitivity reaction Smoking ( regular irregular ) Excessive alcohol drinking ( approximately 30 g alcohol per day ) Positive drug screen know admitted drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>genotype</keyword>
	<keyword>bioavailability</keyword>
	<keyword>metabolic clearance</keyword>
</DOC>